The St. Jude Comprehensive Cancer Center (SJCCC) leadership views the design and implementation of investigator-initiated clinical trials as a top priority. This activity is especially valued when it translates discoveries made in SJCCC basic research laboratories to novel therapies that promise to improve the survival of children with cancer. The EPCRS provides an important mechanism of support this work enabling investigators to conduct high-priority translational studies that are not typically supported by other funding mechanisms. The EPCRS supports clinical research nurses (CRA-RNs) and clinical research associates (CRAs) dedicated to the conduct and completion of these innovative pilot and Phase I investigator-initiated trials within the SJCCC. Clinical research personnel supported by the EPCRS help manage and ensure the success of these protocols by providing a broad range of services including: maintaining protocol-specific research data;ensuring protocol compliance;preparing progress and safety reports;coordinating of specimen collection and compliance with the numerous biological and pharmacological endpoints;and coordinating the abstraction and assimilation of necessary data for analyses and reporting. Many of our EPCRS supported protocols involve an IND or IDE and/or novel agents developed within the SJCCC;thus, additional regulatory functions are required. Candidate trials for EPCRS are first identified within the SJCCC Programs and reviewed and approved by the SJCCC Director and the Associate Director for Clinical Research, who also provide budget oversight. Funding is requested for an appropriate portion of salary support for clinical research nurses, clinical research associates (CRAs), and study coordinators for work supporting EPCRS-eligible trials.

Public Health Relevance

Early Phase Clinical Research Support provides funding for research nurses and data managers directly involved in the conduct of EPCRS-eligible trials. This funding enhances the SJCCC mission to develop innovative new pediatric cancer treatment strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA021765-35
Application #
8634438
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-01
Project End
2019-02-28
Budget Start
2014-06-09
Budget End
2015-02-28
Support Year
35
Fiscal Year
2014
Total Cost
$239,125
Indirect Cost
$103,545
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
ElInati, Elias; Russell, Helen R; Ojarikre, Obah A et al. (2017) DNA damage response protein TOPBP1 regulates X chromosome silencing in the mammalian germ line. Proc Natl Acad Sci U S A 114:12536-12541
Gibson, Todd M; Li, Zhenghong; Green, Daniel M et al. (2017) Blood Pressure Status in Adult Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 26:1705-1713
Scott, Daniel C; Hammill, Jared T; Min, Jaeki et al. (2017) Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. Nat Chem Biol 13:850-857
Patel, Y T; Daryani, V M; Patel, P et al. (2017) Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. CPT Pharmacometrics Syst Pharmacol 6:305-314
Penkert, Rhiannon R; Jones, Bart G; H├Ącker, Hans et al. (2017) Vitamin A differentially regulates cytokine expression in respiratory epithelial and macrophage cell lines. Cytokine 91:1-5
Howell, Carrie R; Wilson, Carmen L; Ehrhardt, Matthew J et al. (2017) Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study. Cancer :
Talleur, Aimee C; Triplett, Brandon M; Federico, Sara et al. (2017) Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Hapl Biol Blood Marrow Transplant 23:1910-1917
Wu, Jianrong (2017) Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model. Stat Biopharm Res 9:25-34
Svolos, P; Reddick, W E; Edwards, A et al. (2017) Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation. AJNR Am J Neuroradiol 38:1235-1241
Lin, Wenwei; Goktug, Asli N; Wu, Jing et al. (2017) High-Throughput Screening Identifies 1,4,5-Substituted 1,2,3-Triazole Analogs as Potent and Specific Antagonists of Pregnane X Receptor. Assay Drug Dev Technol 15:383-394

Showing the most recent 10 out of 6607 publications